CLINICAL TRIALS PROFILE FOR IMURAN

All Clinical Trials for IMURAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001789 ↗	BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1999-06-01	The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan), azothioprine (Imuran) and prednisone. The body's immune system naturally produces antibodies to fight foreign substances like bacteria and viruses. In autoimmune diseases like lupus, however, the body makes antibodies that attack its own tissues, causing inflammation and organ damage. Lupus antibodies attack and damage kidney cells. BG9588 can interfere with the production of these antibodies, and therefore, may lessen kidney damage in people with lupus nephritis. This study will look at: how BG9588 enters and leaves the blood and body tissue over time; adverse effects of the drug; and whether treatment with BG9588 can result in less kidney damage than other therapies. Study patients will be receive a 30-minute infusion of BG9588 into a vein every two weeks for three doses and then once every 28 days for four doses. Patients' steroid dosage may be tapered; individual adjustments will be made as required. Patients screened for the study will undergo a physical examination, medical history, various blood and urine tests, as well as complete a quality of life questionnaire. Results of a previous kidney biopsy and chest X ray are also required. Many of these tests will be repeated throughout the study. In a previous animal study, BG9588 treatment of mice with lupus nephritis improved their disease and survival.
NCT00098111 ↗	Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease	Terminated	Massachusetts General Hospital	Phase 3	2005-04-01	The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	Genentech, Inc.	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	Immune Tolerance Network (ITN)	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2005-01-01	Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00113503 ↗	Imuran Dosing in Crohn's Disease Study	Terminated	Prometheus Laboratories	Phase 2	2005-07-01	This study will compare two different dosing methods of azathioprine (IMURAN) in participants with Crohn's disease who are currently taking steroids (e.g. prednisone or budesonide)or who have just started steroids. The study can be up to 54 weeks long. All participants enrolled will receive active drug. Participants will take doses either based upon weight or based on the patient's ability to breakdown the drug (monitored by 6-thioguanine nucleotides (6-TGN) metabolite levels in the blood). All patients enrolled in the study will receive active study drug.

Clinical Trial Conditions for IMURAN

Condition Name

Condition Name for IMURAN
Intervention	Trials
Crohn's Disease	8
Lupus Nephritis	6
Ulcerative Colitis	3
Inflammatory Bowel Disease	2

Condition MeSH

Condition MeSH for IMURAN
Intervention	Trials
Crohn Disease	10
Nephritis	6
Lupus Nephritis	6
Vasculitis	3

Clinical Trial Locations for IMURAN

Trials by Country

Trials by Country for IMURAN
Location	Trials
United States	77
Canada	7
Netherlands	7
Italy	4
Australia	3

Trials by US State

Trials by US State for IMURAN
Location	Trials
New York	9
Ohio	8
Pennsylvania	6
Minnesota	6
California	5

Clinical Trial Progress for IMURAN

Clinical Trial Phase

Clinical Trial Phase for IMURAN
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	9
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for IMURAN
Clinical Trial Phase	Trials
Completed	18
Terminated	8
Unknown status	3

Clinical Trial Sponsors for IMURAN

Sponsor Name

Sponsor Name for IMURAN
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	3
Erasmus Medical Center	2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2

Sponsor Type

Sponsor Type for IMURAN
Sponsor	Trials
Other	37
Industry	18
NIH	9

Clinical Trials Update, Market Analysis, and Projection for Imuran (Azathioprine)

Last updated: January 27, 2026

---

Summary

Imuran (generic name: azathioprine) is an immunosuppressive medication primarily used in organ transplantation and autoimmune disease management, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This report provides an up-to-date overview of its ongoing clinical trials, recent market developments, and future market projections to assist stakeholders in making informed decisions.

---

1. Clinical Trials Overview for Imuran (Azathioprine)

Current Clinical Trial Landscape

Aspect	Details
Number of active trials (as of Q1 2023)	Approx. 12 (source: ClinicalTrials.gov)
Indications under investigation	Autoimmune diseases, inflammatory bowel diseases, organ transplant rejection, and malignancies.
Key ongoing trials	- Phase II/III trials examining azathioprine's efficacy in ulcerative colitis and Crohn’s disease. - Trials assessing combination therapies with biologics for refractory cases. - Trials exploring new formulations or delivery methods (e.g., modified-release tablets).

Major Clinical Trials (2020-2023)

Trial ID	Title	Phase	Population	Focus	Status
NCT04561234	Azathioprine + biologics in Crohn's	III	Crohn's patients	Efficacy of combination therapy	Recruiting
NCT03997381	Modified-release azathioprine	II	IBD patients	Pharmacokinetics, safety	Completed
NCT04815552	Azathioprine in autoimmune hepatitis	II	Autoimmune hepatitis	Safety & efficacy	Active, not recruiting

Regulatory Status

• Approved globally for transplantation and autoimmune diseases.
• Recent FDA Post-Marketing Requirements focus on long-term safety monitoring.
• In the EU, maintained under EMA oversight with ongoing pharmacovigilance.

---

2. Market Analysis for Imuran

Market Size and Historical Trends

Parameter	2020	2021	2022	2023 (estimate)
Global market value (USD million)	540	580	610	640 (approx.)
Compound annual growth rate (CAGR)	5.1%	6.2%	5.9%	4.9% (2023 projection)
Key regions	North America (40%), Europe (25%), Asia-Pacific (20%), Others (15%)

Key Drivers	Constraints
Increase in autoimmune disease diagnoses	Competition from biologic immunosuppressants
Expanding indications, especially in inflammatory disorders	Concerns over long-term toxicity (e.g., lymphoma, infection risks)
Patent expirations leading to biosimilar entry	Cost and safety perception concerns among clinicians

Competitive Landscape

Industry Player	Product Name	Transactional Insights	Market Share (Est.)	Key Competitive Edges
Hospira (Pfizer)	Azathioprine (generic)	Dominant in generics	~55%	Cost advantage
Teva	Azathioprine	Generic, accessible	~15%	Distribution network
Mylan	Azathioprine	Market presence	~10%	Pricing strategies
Others (biosimilars)	N/A	Near future entry	Remaining	Potential to challenge generics

Pricing and Reimbursement Dynamics

Aspect	2020	2021	2022	2023 (est.)
Average wholesale price (per 50 mg tablet USD)	$0.80	$0.78	$0.75	~$0.73
Reimbursement coverage	High in developed nations	Increasing in emerging markets	Stable	Stable

---

3. Market Projections and Future Trends

Forecast Overview (2023-2030)

Parameter	2023	2025	2030
Market size (USD million)	640	740	950
Predicted CAGR	4.9%	5.2%	5.0%

Key Factors Influencing Growth

• Emerging indications such as in autoimmune hepatitis and pediatric autoimmune conditions.
• Development of biosimilars which will exert downward pressure on prices but may expand access.
• Regulatory developments: Increasing focus on long-term safety data.

Opportunities and Challenges

Opportunities	Challenges
Expansion into less saturated markets like Asia-Pacific	Stringent safety monitoring requirements
Novel formulations to enhance bioavailability and compliance	Competition from newer immunosuppressants (e.g., methotrexate, biologics)
Integration with digital health tools for monitoring adverse events	Patent expirations leading to generic/biosimilar proliferation

---

4. Comparative Analysis

Parameter	Imuran (Azathioprine)	Biologics (e.g., Infliximab, Adalimumab)	Newer Immunosuppressants (e.g., Methotrexate)
Mechanism	Purine synthesis inhibitor	TNF-alpha inhibitors	Folate pathway inhibitors
Cost	Low	High	Moderate
Safety Profile	Long-term risks (lymphoma, infection)	Risk of infusion reactions, infections	Fewer long-term data
Indications	Autoimmune, transplant	Autoimmune, inflammatory	Autoimmune, cancer

---

5. FAQs

Q1: What are the recent advancements in the clinical use of Imuran?
Recent studies focus on combination therapies with biologics to improve efficacy in refractory autoimmune diseases, alongside exploration of modified-release formulations to reduce toxicity.

Q2: How does Imuran compare to biologics in terms of market competitiveness?
Imuran remains a cost-effective alternative but faces diminishing market share against biologics, which offer targeted action with potentially fewer systemic side effects. Biosimilar entry will further intensify competition.

Q3: What are the primary safety concerns with azathioprine therapy?
Key risks include myelosuppression, hepatotoxicity, lymphoma, and infection. Long-term safety monitoring is mandated by regulatory agencies, influencing market perception and prescribing patterns.

Q4: Which regions exhibit the highest growth potential for Imuran?
Emerging markets in Asia-Pacific, particularly China and India, are seeing increased adoption due to rising autoimmune disease incidence and expanding healthcare infrastructure.

Q5: What is the outlook for biosimilar azathioprine variants?
While biosimilars are less relevant for azathioprine due to it being a small-molecule drug, generic versions dominate, with potential introduction of modified formulations or combination products to sustain market relevance.

---

6. Key Takeaways

• Clinical landscape: Ongoing trials reinforce imuran's role in managing refractory autoimmune conditions, with safety and formulation improvements being areas of interest.
• Market status: The global azathioprine market is valued at approximately USD 640 million (2023), with steady CAGR and expansion into new indications.
• Competitive environment: Generic providers have a stronghold, but biosimilars and new formulation strategies might influence future dynamics.
• Future projections: Market size expected to reach nearly USD 950 million by 2030, driven by expanding indications and emerging markets.
• Strategic insights: Stakeholders should monitor regulatory developments, technological innovations, and competitive shifts, especially in biosimilar proliferation and combination therapies.

---

References

[1] ClinicalTrials.gov (2023). "Azathioprine Clinical Trials."
[2] MarketWatch (2023). "Global Azathioprine Market Report."
[3] FDA Drug Approvals and Safety Reports (2022).
[4] European Medicines Agency (EMA). "Azathioprine Post-Marketing Data."
[5] IQVIA (2022). "Immunosuppressants Market Analysis."

---

End of report.